Who
Mona Ashiya
Director
Company insider
Files Form 4 as: Director, Yarrow Bioscience; Director, Shattuck Labs; Director and 10% owner, Disc Medicine; Director and 10% owner, Sierra Oncology.
In numbers
- Trades disclosed
- 94
- Buys
- 3
- Sells
- 12
- Bought
- $11.0M
- Sold
- $52.7M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 29 Nov 2019
- Last trade
- 27 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 27 Jul 2026filed 29 Jul 2026 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,435 at $0.00 | filing |
| 27 Jul 2026filed 29 Jul 2026 | YARW Yarrow Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,435 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code P | —1,041,667 | filing |
| 11 Jun 2026filed 15 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code P | —208,333 | filing |
| 11 Jun 2026filed 15 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code P | —1,041,667 | filing |
| 11 Jun 2026filed 15 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code P | —208,333 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —15,366,490 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,073,298 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —15,366,490 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —15,366,490 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,073,298 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —15,366,490 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,073,298 | filing |
| 8 Jun 2026filed 9 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,073,298 | filing |
| 29 May 2026filed 2 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 28 Aug 2025filed 2 Sep 2025 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,300 at $0.00 | filing |
| 25 Aug 2025filed 2 Sep 2025 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code P | —10,111,384 | filing |
| 25 Aug 2025filed 2 Sep 2025 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,022,277 | filing |
| 25 Aug 2025filed 2 Sep 2025 | STTK Shattuck Labsoption or derivative · Biotechnology | SEC FORM 4 Code P | —15,366,490 | filing |
News
Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded WarrantsIRON · manilatimes.net · 19 Oct 2026Stock Traders Purchase High Volume of Disc Medicine Put Options (NASDAQ:IRON)IRON · dailypolitical.com · 19 Oct 2026Disc Medicine Stock Soars 31% After Bitopertin Hits All Goals in Pivotal Trial for Rare Sunlight DisorderIRON · ibtimes.com.au · 19 Oct 2026
0 headlines in the last 90 days name Mona Ashiya; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.